1. Home
  2. HTLM vs ALGS Comparison

HTLM vs ALGS Comparison

Compare HTLM & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTLM
  • ALGS
  • Stock Information
  • Founded
  • HTLM 2014
  • ALGS 2018
  • Country
  • HTLM Singapore
  • ALGS United States
  • Employees
  • HTLM N/A
  • ALGS N/A
  • Industry
  • HTLM
  • ALGS Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTLM
  • ALGS Health Care
  • Exchange
  • HTLM NYSE
  • ALGS Nasdaq
  • Market Cap
  • HTLM 117.5M
  • ALGS 118.8M
  • IPO Year
  • HTLM 2024
  • ALGS 2020
  • Fundamental
  • Price
  • HTLM $7.99
  • ALGS $34.24
  • Analyst Decision
  • HTLM
  • ALGS Strong Buy
  • Analyst Count
  • HTLM 0
  • ALGS 1
  • Target Price
  • HTLM N/A
  • ALGS $75.00
  • AVG Volume (30 Days)
  • HTLM 103.1K
  • ALGS 435.1K
  • Earning Date
  • HTLM 12-25-2024
  • ALGS 03-11-2025
  • Dividend Yield
  • HTLM N/A
  • ALGS N/A
  • EPS Growth
  • HTLM N/A
  • ALGS N/A
  • EPS
  • HTLM N/A
  • ALGS N/A
  • Revenue
  • HTLM $4,563,246.00
  • ALGS $5,997,000.00
  • Revenue This Year
  • HTLM N/A
  • ALGS N/A
  • Revenue Next Year
  • HTLM N/A
  • ALGS N/A
  • P/E Ratio
  • HTLM N/A
  • ALGS N/A
  • Revenue Growth
  • HTLM N/A
  • ALGS N/A
  • 52 Week Low
  • HTLM $2.57
  • ALGS $6.76
  • 52 Week High
  • HTLM $13.74
  • ALGS $46.80
  • Technical
  • Relative Strength Index (RSI)
  • HTLM N/A
  • ALGS 50.11
  • Support Level
  • HTLM N/A
  • ALGS $30.31
  • Resistance Level
  • HTLM N/A
  • ALGS $35.30
  • Average True Range (ATR)
  • HTLM 0.00
  • ALGS 4.64
  • MACD
  • HTLM 0.00
  • ALGS -1.68
  • Stochastic Oscillator
  • HTLM 0.00
  • ALGS 32.83

About HTLM HOMESTOLIFE LTD

Homestolife Ltd is a home furniture retailers that offers and sells customized furniture solutions in Singapore. It has six retail store locations that sell furniture manufactured from China and other Asian countries.

About ALGS Aligos Therapeutics Inc.

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Share on Social Networks: